Clofazimine in the treatment of multidrug-resistant tuberculosis

Clinical Microbiology and Infection

Volumn 18, Issue 11, 2012, Pages 1104-1110

  Xu, H B ^a   Jiang, R H ^b   Xiao, H P ^b  

^a TENTH PEOPLE S HOSPITAL OF TONGJI UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Clofazimine; Extensively drug resistant; Multidrug resistance; Treatment outcomes; Tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIALLERGIC AGENT; ANTIEMETIC AGENT; AZITHROMYCIN; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; ERYTHROPOIETIN; ETHAMBUTOL; FERROUS SULFATE; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PASINIAZID; PROTIONAMIDE; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN;

ADULT; ANEMIA; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM ISOLATE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CHINA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DIRECTLY OBSERVED THERAPY; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; ICHTHYOSIS; INSOMNIA; LEUKOPENIA; LUNG CAVITATION; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; POLYPHARMACY; PRIORITY JOURNAL; RASH; SKIN DISCOLORATION; SPUTUM CULTURE; SPUTUM SMEAR; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALIA; MYCOBACTERIUM TUBERCULOSIS;

EID: 84867387568     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03716.x     Document Type: Article

References (18)

1. WHO. Global tuberculosis control 2009: epidemiology, strategy, financing [WHO/HTM/TB/2009.411]. http://www.who.int/entity/tb/publications/global_report/2009/pdf/full_report.pdf (accessed on 15 October 2010).
2. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
3. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329: 784-791.
4. Nachega JB, Chaisson RE. Tuberculosis drug resistance. A global threat. Clin Infect Dis 2003; 36 (suppl 1): 24-30.
5. Centers for Disease Control and Prevention. Revised definition of extensively drug-resistant tuberculosis. MMWR 2006; 55: 1176.
6. Barry VC, Belton JG, Conalty ML et al. A new series of phenazines (riminocompounds) with high antituberculosis activity. Nature (London) 1957; 179: 1013-1015.
7. Reddy VM, O'Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother 1999; 43: 615-623.
8. Lu Y, Zheng MQ, Wang B et al. Activities of clofazimine against Mycobacterium tuberculosis in vitro and in vivo. Zhonghua Jie He He Hu Xi Za Zhi. 2008; 31: 752-755.
9. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant TB (MDR-TB) - a report of ten cases. J Infect 2006; 52: 92-96.
10. Anger HA, Dworkin F, Sharma S et al. Linezolid use for treatment of multidrug- resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J Antimicrob Chemother 2010; 65: 775-783.
11. Fortun J, Martin-Davila P, Navas E et al. Linezolid for the treatment of multidrug- resistant tuberculosis. J Antimicrob Chemother 2005; 56: 180-185.
12. Condos R, Hadgiangelis N, Leibert E et al. Case series report of a linezolid- containing regimen for extensively drug-resistant TB. Chest 2008; 134: 187-192.
13. Schecter GF, Scott C, True L et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50: 49-55.
14. Laserson KF, Thorpe LE, Leimane V et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645.
15. Clofazimine. Tuberculosis 2008; 88: 96-99.
16. Mitnick CD, Shin SS, Seung KJ et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-574.
17. Cynamon MH, Klemens SP, Sharpe CA et al. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999; 43: 1189-1191.
18. Rodriguez JC, Cebrian L, Lopez M et al. Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 2004; 53: 441-444.